Page last updated: 2024-09-03

imatinib mesylate and Granulocytic Leukemia

imatinib mesylate has been researched along with Granulocytic Leukemia in 89 studies

Research

Studies (89)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (2.25)18.2507
2000's50 (56.18)29.6817
2010's24 (26.97)24.3611
2020's13 (14.61)2.80

Authors

AuthorsStudies
Adachi, K; Araki, M; Asada, S; Fukushima, T; Fukuyama, T; Goyama, S; Imai, M; Ito, R; Kitamura, T; Komatsu, N; Lamagna, C; Masuda, ES; Mikami, K; Morishita, S; Nagata, M; Takaku, T; Takeda, R; Takizawa, H; Tamura, M; Tanaka, Y; Tsuchiya, S; Umemoto, T; Watanabe, N1
Beg, MMA; Guru, SA; Koner, BC; Mir, R; Saxena, A; Sumi, MP1
Alonso, RA; Ayala, R; Calbacho, M; Carreño-Tarragona, G; Colmenares, R; Cruz-Rojo, J; de la Cruz, J; García-Barrio, N; Gil, R; Gil-Alos, D; Hernández, G; Lopez, N; Martínez-López, J; Meloni, L; Pedrera-Jiménez, M; Pérez-Rey, D; Sánchez-Pina, J; Sanz, A; Serrano-Balazote, P1
Fabarius, A; Haferlach, C; Hehlmann, R; Hochhaus, A; Lauseker, M; Saußele, S; Voskanyan, A1
Jurajda, M; Knight, A; Mayer, J; Piskacek, M; Prochazkova, J; Racil, Z; Zackova, D1
Brewinska-Olchowik, M; Dudka, W; Hoser, G; Klejman, A; Kominek, A; Kusio-Kobialka, M; Machnicki, MM; Mondal, SS; Piwocka, K; Seferynska, I; Stoklosa, T; Swatler, J; Turos-Korgul, L; Wiech, M; Wołczyk, M1
Eşkazan, AE1
Chen, Y; Cheng, F; Cui, Z; Li, Q; Li, W; Zeng, F; Zhang, Y1
Prasad, V; Walia, A1
Ballarò, D; Buffolino, S; Lapietra, G; Limongi, MZ; Mancini, M; Martelli, M; Nanni, M1
Ross, DM1
Gale, RP; Huang, J; Huang, X; Jiang, Q; Liu, B; Qi, F; Zhang, X1
Branford, S; Dang, P; Hughes, TP; Kok, CH; Saunders, VA; Shanmuganathan, N; White, D; Yeung, D1
Bidet, A; Caillot, D; Chollet, C; Delmer, A; Dulucq, S; Gardembas, M; Genet, P; Lippert, E; Mahon, FX; Nicolini, FE1
Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K1
Ankathil, R; Azlan, H; Baba, AA; Elias, MH1
Hawes, V; Lobo, RH; Sasapu, A; Socola, F1
Bilgiş Gazioğlu, S; Birman, H; Candöken, E; Danışman Kalındemirtaş, F; Kuruca, S; Melikoğlu, G1
Cross, NC; Fabarius, A; Gosenca, D; Haferlach, C; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Schwaab, J1
Audureau, E; Garcia-Gonzalez, P; Ladner, J; Saba, J; Tavolacci, MP; Tekinturhan, E1
Aguiar, RC; Apperley, JF; Burbury, K; Cheah, CY; Cross, NC; Dunbar, CE; Forrest, D; Gardembas, M; Genet, P; Gimelfarb, A; Huguet, F; Ito, S; Odenike, O; Patton, N; Pitini, V; Ross, DM; Rousselot, P; Seymour, JF; Smith, G1
Clare-Salzler, MJ; Li, S; Xia, CQ; Xia, T; Xie, C; Yuan, L; Zhang, P1
Passamonti, F1
Endo, F; Jono, H; Kouroki, M; Ohmura, T; Saito, H; Taguchi, K1
Ahn, KS; Cho, JH; Chung, WS; Kim, C; Kim, MB; Kim, SH; Nam, D1
Bogdanovic, A; Elezovic, I; Gotic, M; Jankovic, G; Lekovic, D; Perunicic-Jovanovic, M1
Gupta, S; Kumar, H; Raj, U; Srivastava, S; Varadwaj, PK1
Adachi, S; Horibe, K; Hotta, N; Ishii, E; Ito, M; Kajiwara, R; Kurosawa, H; Mizutani, S; Moriya Saito, A; Muramatsu, H; Okada, M; Shima, H; Shimada, H; Tanizawa, A; Tono, C; Watanabe, A; Yuza, Y1
Hongeng, S; Ratanachamnong, P; Slukvin, I; Srihirun, S; Suknuntha, K; Thita, T; Togarrati, PP; Wongtrakoongate, P1
Bousema, MT; Hayes, DP; Kardaun, SH; Kramer, MH; Timmer-de Mik, L1
Berretta, S; Chiarenza, A; Conticello, C; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Stagno, F; Tibullo, D1
Albitar, M; Bornmann, W; Estrov, Z; Faderl, S; Harris, D; Hazan-Halevy, I; Kantarjian, HM; Liu, Z; Maxwell, D; Pal, A; Peng, Z; Van, Q1
Chan, AL; Hsieh, HJ; Lin, SJ1
Breitscheidel, L1
Abuav, R; Goldenberg, G; High, W; Pass, C; Skupsky, H1
Tojo, A1
Kiyokawa, N; Kiyotani, C; Mori, T1
Demetri, GD; Ganjoo, KN; Jacobs, C; Patel, S1
Bergua, A; Chankiewitz, E; Mackensen, A; Scholz, GA; Spriewald, BM1
Crawford, M; Dollins, CM; Grant, S; Graves, LM; Hammond, SM; Nana-Sinkam, SP; Richards, KL; Zimmerman, EI1
Feng, YQ; Li, X; Liu, J; Lü, S; Luo, Q; Wang, F; Wu, J; Xiong, S1
Chu, DT1
Hoffman, R; Kiladjian, JJ; Mesa, RA1
Eskander, RN; Herbst, KD; Kelly, TF; Tarsa, M1
Chang, CS; Hsu, CN; Lin, MT; Yang, YH1
Sawyers, CL1
Jedrzejczak, WW; Nurzyńska, D1
Frassoni, F; Luzzatto, L; Melo, JV1
Asaka, M; Hirabayashi, T; Hori, K; Kajimoto, S; Kondo, T; Masuda, Y; Nakajo, S; Nakaya, K; Nishida, A1
Almenara, J; Conrad, D; Dent, P; Grant, S; Krystal, G; Rahmani, M; Subler, M; Varticovski, L; Yu, C1
Griffin, JD; Sattler, M; Scheijen, B; Weisberg, E1
Ball, G; Beran, M; Cortes-Franco, JE; Divoky, V; Gatto, S; Kantarjian, HM; Keating, MJ; Milella, M; Onida, F; Pham, L; Ricci, C; Scappini, B; Verstovsek, S1
Nakajima, A; Ohyashiki, K; Sashida, G; Shimamoto, T; Sumi, M; Tauchi, T1
Hishita, T; Ichiyama, S; Miura, Y; Mizutani, C; Nishihara, T; Tohyama, K; Tohyama, Y; Uchiyama, T1
Beck, J; Breitenbuecher, F; Duyster, J; Fischer, T; Gschaidmeier, H; Hess, G; Huber, C; Kindler, T; Kirkpatrick, CJ; Marx, A; Peschel, C; Theobald, M; Weinkauf, B1
Krystal, GW1
Becton, DL; Chang, MN; Dahl, GV; Douglas, L; Kinnunen, P; Lacayo, NJ; Meshinchi, S; Radich, JP; Ravindranath, Y; Sikic, BI; Stuber, CM; Tibshirani, R; Wahab, R; Wang, Y; Weinstein, H; Willman, CL; Yu, R1
Anderson, K; Atadja, P; Catley, L; Cavazza, C; Fuerst, P; Griffin, JD; Kujawa, J; Remiszewski, S; Weisberg, E1
Annavarapu, S; Atadja, P; Bali, P; Bhalla, K; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Sondarva, G1
Advani, AS1
Amabile, M; Arpinati, M; Baccarani, M; Basi, C; Bocchia, M; Candoni, A; Cilloni, D; Fanin, R; Gaitani, S; Gottardi, E; Lauria, F; Maderna, M; Malagola, M; Marrè, MC; Martinelli, G; Ottaviani, E; Paolini, S; Piccaluga, PP; Rancati, F; Rondoni, M; Russo, D; Saglio, G; Vinaccia, V; Visani, G1
Bullorsky, E; Ricchione, D; Saxton, R; Schamun, A; Stemmelin, G1
Creutzig, U; Goemans, BF; Hählen, K; Harlow, A; Heinrich, MC; Kaspers, GJ; Loonen, AH; Meshinchi, S; Miller, M; Reinhardt, D; Zimmermann, M; Zwaan, CM1
Grever, MR1
Han, HY; Han, JY; Jeong, JS; Kim, HJ; Kwak, JY; Kwon, HC; Park, JI; Park, TH; Seo, C1
Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B1
Dumur, CI; Ferreira-Gonzalez, A; Fossey, SC; Garrett, CT; Vnencak-Jones, CL1
Ikeda, A; Moore, TB; Sakamoto, KM; Shankar, DB; Tamanoi, F; Watanabe, M1
Fladmark, KE; Gjertsen, BT; Hovland, R; Oveland, E; Wergeland, L1
Corbacioglu, S; Debatin, KM; Fulda, S; Kilic, M; Reinhardt, D; Westhoff, MA1
Chan, LC; Liu, HS; So, CC; Wan, TS; Wong, ML; Yip, SF1
Sell, S1
Bardini, M; Blasi, F; Calabretta, B; Corradini, F; Ferrari-Amorotti, G; Iotti, G; Lidonnici, MR; Martinez, R; Ronchetti, M; Rosafio, C; Zhang, Y1
Campiani, G; Greene, LM; Kelly, L; Lawler, M; Onnis, V; Williams, DC; Zisterer, DM1
Aulitzky, W; Cortes, J; Döhner, H; Fischer, T; Heidel, F; Huber, C; Kantarjian, H; Kindler, T; Letvak, L; Rücker, FG1
Aulitzky, WE; Beneke, H; Cross, NC; Del Valle, F; Diecker, F; Döhner, H; Erben, P; Haferlach, C; Haferlach, T; Hehlmann, R; Hochhaus, A; Hodges, E; Metzgeroth, G; Mix, J; Müller, L; Müller, MC; Müller-Hermelink, K; Popp, H; Reiter, A; Schmitz, N; Schnittger, S; Schuld, P; Schulte, C; Score, J; Siebert, R; Walz, C; Whittaker, SJ; Wittkowsky, G1
Bona, R; Kaplan, AA; Shafique, S1
Apperley, JF; Chaidos, A; Kanfer, E1
Clark, RE; Giannoudis, A; Lane, S; Pirmohamed, M; Wang, L; Williamson, P1
Antoniadis, A; Kalala, F; Kokoviadou, K; Korantzis, I; Plastiras, D; Speletas, M; Vyzantiadis, TA1
Ates, H; Pehlivan, M; Sercan, HO; Sercan, Z; Simsek, O1
Craddock, C1
Belotti, D; Bertazzoli, C; Biondi, A; Corneo, GM; Di Nicola, M; Fanelli, M; Gambacorti-Passerini, C; le Coutre, P; Lydon, NB; Marchesi, E; Mologni, L; Pogliani, E1
Dan, S; Kizaki, A; Mashima, T; Naito, M; Seimiya, H; Tsuruo, T1
Brown, E; Lewis, PH; Nocera, J1
Pestell, K1
Casadevall, N; Delmer, A; Legrand, O; Marie, JP; Rio, B; Ugo, V1
Bown, N; Capdeville, R; Chang, J; Connors, S; Melo, JV; O'Brien, SG; Vieira, SA1

Reviews

17 review(s) available for imatinib mesylate and Granulocytic Leukemia

ArticleYear
Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature.
    Journal of global oncology, 2018, Volume: 4

    Topics: Antineoplastic Agents; Biomarkers; Bone Marrow; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myeloid; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Tumor Lysis Syndrome

2018
[Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
    Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles

2009
[Clinical problems in the treatment of myeloid leukemia in childhood].
    Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Communicable Diseases; Down Syndrome; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk

2009
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:10

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine

2010
The renaissance of interferon therapy for the treatment of myeloid malignancies.
    Blood, 2011, May-05, Volume: 117, Issue:18

    Topics: Apoptosis; Benzamides; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid; Mastocytosis; Neoplastic Stem Cells; Neovascularization, Pathologic; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recombinant Proteins; Thrombocythemia, Essential

2011
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
    Cancer cell, 2002, Volume: 1, Issue:5

    Topics: Acute Disease; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Cell Surface

2002
[Oncogene products inhibitors in the treatment of cancer].
    Polskie Archiwum Medycyny Wewnetrznej, 2002, Volume: 107, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myeloid; Oncogene Proteins; Oncogenes; Piperazines; Pyrimidines

2002
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Advances in experimental medicine and biology, 2003, Volume: 532

    Topics: Animals; Benzamides; Binding Sites; Clinical Trials as Topic; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myeloid; Mice; Mutation; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; src Homology Domains

2003
Imatinib mesylate (STI571) for myeloid malignancies other than CML.
    Leukemia research, 2004, Volume: 28 Suppl 1

    Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mastocytosis, Systemic; Myeloproliferative Disorders; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines

2004
C-kit as a target in the treatment of acute myelogenous leukemia.
    Current hematology reports, 2005, Volume: 4, Issue:1

    Topics: Acute Disease; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Hematopoiesis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid; Mice; Oxindoles; Piperazines; Propionates; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor

2005
New drugs in acute myeloid leukemia.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:8

    Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Thionucleotides

2003
Molecular targets and the treatment of myeloid leukemia.
    Molecular genetics and metabolism, 2006, Volume: 88, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Piperazines; Pyrimidines; ras Proteins; Receptor Protein-Tyrosine Kinases; Translocation, Genetic; Tretinoin

2006
Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies.
    Current pharmaceutical biotechnology, 2006, Volume: 7, Issue:3

    Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Signal Transduction

2006
Leukemia: stem cells, maturation arrest, and differentiation therapy.
    Stem cell reviews, 2005, Volume: 1, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myeloid; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Pyrimidines

2005
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
    Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:2

    Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous

2007
Molecularly targeted therapy in myeloid leukaemias.
    Clinical medicine (London, England), 2007, Volume: 7, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome

2007
[Update on malignant hemopathies].
    Bulletin du cancer, 2002, Volume: 89, Issue:1

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotoxins; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Lymphoma; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Tretinoin

2002

Trials

5 trial(s) available for imatinib mesylate and Granulocytic Leukemia

ArticleYear
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
    Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:12

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Edema; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome

2017
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
    Blood, 2004, May-15, Volume: 103, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Count; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myeloid; Male; Middle Aged; Phosphorylation; Pilot Projects; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy; Treatment Outcome

2004
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
    Cancer, 2007, Mar-01, Volume: 109, Issue:5

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Stem Cell Factor; Survival Rate; Treatment Outcome

2007
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
    Leukemia, 2007, Volume: 21, Issue:6

    Topics: Acute Disease; Adult; Aged; Benzamides; Disease-Free Survival; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Nucleophosmin; Oncogene Proteins, Fusion; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction

2007
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
    Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line, Tumor; Disease-Free Survival; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myeloid; Middle Aged; Mutation; Neoplasm Proteins; Octamer Transcription Factor-1; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Regression Analysis; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Treatment Outcome

2008

Other Studies

67 other study(ies) available for imatinib mesylate and Granulocytic Leukemia

ArticleYear
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors.
    Nature communications, 2022, 01-12, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents; Chronic Disease; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Interleukin-1 Receptor-Associated Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Mice; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors

2022
Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
    BMC cancer, 2022, Apr-14, Volume: 22, Issue:1

    Topics: Apoptosis; Cell Cycle; Chronic Disease; Cytokines; Disease Progression; DNA; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Surveys and Questionnaires; Tumor Suppressor Protein p14ARF

2022
Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network.
    Blood cancer journal, 2022, 06-24, Volume: 12, Issue:6

    Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid

2022
Impact of emerging ACA on survival in chronic myeloid leukemia (CML).
    Leukemia, 2022, Volume: 36, Issue:10

    Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid

2022
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
    Cancer immunology, immunotherapy : CII, 2023, Volume: 72, Issue:5

    Topics: Cell Line; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets

2023
Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells.
    BMC cancer, 2022, Dec-02, Volume: 22, Issue:1

    Topics: Animals; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mice; Protein Kinase Inhibitors; Signal Transduction; STAT5 Transcription Factor

2022
Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!
    Cancer, 2023, 02-15, Volume: 129, Issue:4

    Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Treatment Outcome

2023
Reply to "Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!"
    Cancer, 2023, 02-15, Volume: 129, Issue:4

    Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid

2023
Is it time to reconsider molecular response milestones in chronic myeloid leukemia?
    American journal of hematology, 2023, Volume: 98, Issue:4

    Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Protein Kinase Inhibitors

2023
Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.
    Leukemia research, 2023, Volume: 126

    Topics: Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Polycythemia Vera

2023
Single cells tell multiple tales in CML.
    Blood, 2023, 06-01, Volume: 141, Issue:22

    Topics: Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid

2023
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy.
    Leukemia, 2023, Volume: 37, Issue:9

    Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid

2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.
    Blood cancer journal, 2023, 09-11, Volume: 13, Issue:1

    Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Splenomegaly

2023
Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.
    British journal of haematology, 2018, Volume: 182, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Gene Rearrangement; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Oncogene Proteins, Fusion; Real-Time Polymerase Chain Reaction

2018
Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients.
    Cardiovascular & hematological disorders drug targets, 2018, Volume: 18, Issue:3

    Topics: Chronic Disease; DNA Methylation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid; Promoter Regions, Genetic; Suppressor of Cytokine Signaling 1 Protein

2018
Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method
    Balkan medical journal, 2019, 02-28, Volume: 36, Issue:2

    Topics: Antineoplastic Agents; Cytotoxins; Data Analysis; Flavonoids; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid

2019
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
    Leukemia, 2013, Volume: 27, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Eosinophilia; Follow-Up Studies; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lymphoma, T-Cell; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Myeloid; Survival Rate

2013
Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program.
    BMC health services research, 2013, Aug-10, Volume: 13

    Topics: Antineoplastic Agents; Benzamides; Developing Countries; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Health Services Accessibility; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Quality Improvement; Survival

2013
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
    Blood, 2014, Jun-05, Volume: 123, Issue:23

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Eosinophilia; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myeloid; Male; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Translocation, Genetic; Young Adult

2014
C-Abl inhibitor imatinib enhances insulin production by β cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Animals; Benzamides; Cell Line; Gene Expression Regulation; Glucose; Glucose Transporter Type 2; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Imatinib Mesylate; Insulin; Insulin-Secreting Cells; Leukemia, Myeloid; Mice; Peptide Biosynthesis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; RNA, Small Interfering; Trans-Activators; Transcription Factors; Zebrafish Proteins

2014
PDGFRB disease: right diagnosis to prolong survival.
    Blood, 2014, Jun-05, Volume: 123, Issue:23

    Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta

2014
Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia.
    Pediatrics international : official journal of the Japan Pediatric Society, 2014, Volume: 56, Issue:4

    Topics: Anticonvulsants; Carbamazepine; Child; Drug Interactions; Epilepsy; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Protein Kinase Inhibitors

2014
The hydrolysed products of iridoid glycosides can enhance imatinib mesylate-induced apoptosis in human myeloid leukaemia cells.
    Phytotherapy research : PTR, 2015, Volume: 29, Issue:3

    Topics: Apoptosis; Benzamides; Caspase 3; Cell Proliferation; CSK Tyrosine-Protein Kinase; Down-Regulation; Humans; Imatinib Mesylate; Iridoid Glucosides; Iridoid Glycosides; Janus Kinase 2; K562 Cells; Leukemia, Myeloid; Phosphorylation; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; STAT5 Transcription Factor

2015
Diagnostic challenges during pretreatment long-term follow-up in a patient with FIP1L1-PDGFRA-positive eosinophilia.
    Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzamides; Eosinophilia; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome

2015
Identification of Dual Natural Inhibitors for Chronic Myeloid Leukemia by Virtual Screening, Molecular Dynamics Simulation and ADMET Analysis.
    Interdisciplinary sciences, computational life sciences, 2016, Volume: 8, Issue:3

    Topics: Animals; Antineoplastic Agents; Computational Biology; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myeloid; Molecular Dynamics Simulation

2016
Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia, Myeloid; Leukostasis; Male; Retrospective Studies; Young Adult

2016
Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines.
    International journal of hematology, 2017, Volume: 105, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Leukemia, Myeloid; Leukocytes, Mononuclear; Receptor Cross-Talk; Sulfonamides; Wnt Signaling Pathway

2017
Imatinib-induced pseudoporphyria.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:6

    Topics: Adult; Antineoplastic Agents; Benzamides; Cytarabine; Drug Eruptions; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Piperazines; Porphyrias; Pyrimidines

2009
Effects of imatinib mesylate in osteoblastogenesis.
    Experimental hematology, 2009, Volume: 37, Issue:4

    Topics: Antineoplastic Agents; Base Sequence; Benzamides; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mesenchymal Stem Cells; Molecular Sequence Data; Osteoblasts; Osteogenesis; Piperazines; Pyrimidines; Reference Standards; Reverse Transcriptase Polymerase Chain Reaction

2009
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
    Cancer research, 2009, May-01, Volume: 69, Issue:9

    Topics: Acute Disease; Apoptosis; Benzamides; Caspases; Cell Growth Processes; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mutation; Oncogene Protein v-akt; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyridines; Pyrimidines; STAT3 Transcription Factor; Stem Cell Factor; Thiazoles

2009
Stevens-Johnson syndrome induced by combination of imatinib and allopurinol.
    Chemotherapy, 2009, Volume: 55, Issue:4

    Topics: Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Female; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Leukemia, Myeloid; Piperazines; Pyrimidines; Stevens-Johnson Syndrome

2009
Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Journal of medical economics, 2008, Volume: 11, Issue:4

    Topics: Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Cost-Benefit Analysis; Germany; Humans; Imatinib Mesylate; Leukemia, Myeloid; Markov Chains; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Stem Cell Transplantation; Transplantation, Homologous; Young Adult

2008
Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia.
    Journal of cutaneous pathology, 2010, Volume: 37, Issue:8

    Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lichen Sclerosus et Atrophicus; Piperazines; Pyrimidines

2010
Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.
    Leukemia & lymphoma, 2009, Volume: 50, Issue:11

    Topics: Acute Disease; Aged; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2009
[Fundus leucaemicus as first manifestation of chronic myeloid leukemia. Diagnosis and monitoring with OCT under treatment with imatinib and interferon-alpha].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2010, Volume: 107, Issue:4

    Topics: Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid; Male; Piperazines; Pyrimidines; Retinal Diseases; Tomography, Optical Coherence; Treatment Outcome; Young Adult

2010
Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.
    Molecular pharmacology, 2010, Volume: 78, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Calcitriol; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; src-Family Kinases

2010
Inhibitor screening of protein kinases using MALDI-TOF MS combined with separation and enrichment of phosphopeptides by TiO2 nanoparticle deposited capillary column.
    The Analyst, 2010, Volume: 135, Issue:11

    Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myeloid; Nanoparticles; Phosphopeptides; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Titanium

2010
Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy.
    The journal of obstetrics and gynaecology research, 2011, Volume: 37, Issue:11

    Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukapheresis; Leukemia, Myeloid; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Remission Induction; Treatment Outcome

2011
Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis.
    BMC health services research, 2012, Oct-16, Volume: 12

    Topics: Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Female; Guideline Adherence; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid; Longitudinal Studies; Male; Middle Aged; Piperazines; Pyrimidines; Taiwan

2012
Imatinib: can one outwit chronic myeloid leukemia?
    Haematologica, 2002, Volume: 87, Issue:9

    Topics: Benzamides; Enzyme Inhibitors; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines

2002
Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).
    Oncogene, 2003, Feb-20, Volume: 22, Issue:7

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Cell Cycle Proteins; Cell Line; Cysteine Proteinase Inhibitors; DNA, Complementary; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genistein; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Kidney; Leukemia, Myeloid; Naphthoquinones; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; U937 Cells

2003
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Cancer research, 2003, May-01, Volume: 63, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Mitochondria; Piperazines; Pyrimidines; Signal Transduction; U937 Cells; Vorinostat

2003
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Haematologica, 2003, Volume: 88, Issue:8

    Topics: Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myeloid; Multienzyme Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Proteasome Endopeptidase Complex; Pyrazines; Pyrimidines

2003
BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-15, Volume: 9, Issue:11

    Topics: Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Mice; Mice, Nude; Oligonucleotides, Antisense; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Survival Analysis; Thionucleotides; Time Factors; Transplantation, Heterologous

2003
Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
    International journal of hematology, 2003, Volume: 78, Issue:3

    Topics: Benzamides; Cell Adhesion; Cell Division; Cell Line, Tumor; Cell Size; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Milk Proteins; Oncogene Protein v-cbl; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-crk; Pyrimidines; Retroviridae Proteins, Oncogenic; STAT5 Transcription Factor; Trans-Activators; Transfection

2003
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
    Blood, 2004, Nov-01, Volume: 104, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Benzamides; Child; Child, Preschool; Cluster Analysis; Core Binding Factor Alpha 3 Subunit; Disease-Free Survival; DNA Helicases; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Imatinib Mesylate; Infant; Leukemia, Myeloid; Mutation; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Transcription Factors; X-linked Nuclear Protein

2004
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
    Leukemia, 2004, Volume: 18, Issue:12

    Topics: Acetylation; Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Marrow Cells; Cell Cycle; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Phosphorylation; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tyrosine

2004
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    Blood, 2005, Feb-15, Volume: 105, Issue:4

    Topics: Acute Disease; Apoptosis; Benzamides; Benzoquinones; Blast Crisis; Cell Line, Tumor; Drug Combinations; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Gene Deletion; Gene Expression Regulation; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Panobinostat; Piperazines; Point Mutation; Polyubiquitin; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Rifabutin

2005
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
    Blood, 2005, Jan-15, Volume: 105, Issue:2

    Topics: Acute Disease; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines

2005
Treatment with cyclosporin A cream for the cutaneous reactions associated with imatinib therapy.
    Blood, 2005, Apr-01, Volume: 105, Issue:7

    Topics: Administration, Topical; Antineoplastic Agents; Benzamides; Cyclosporine; Drug Hypersensitivity; Female; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Piperazines; Pyrimidines

2005
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Leukemia, 2005, Volume: 19, Issue:9

    Topics: Acute Disease; Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; CHO Cells; Core Binding Factors; Cricetinae; Cytogenetic Analysis; Exons; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Genes, ras; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia, Myeloid; Mutation; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Analysis; Transcription Factors; Treatment Outcome

2005
Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells.
    Experimental & molecular medicine, 2005, Oct-31, Volume: 37, Issue:5

    Topics: Amino Acid Sequence; Base Sequence; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Molecular Sequence Data; Mutagenesis, Insertional; Nucleotides; Piperazines; Point Mutation; Pyrimidines

2005
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Haematologica, 2005, Volume: 90 Suppl

    Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine

2005
BCRABL transcript detection by quantitative real-time PCR : are correlated results possible from homebrew assays?
    Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology, 2005, Volume: 9, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity

2005
Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin.
    Blood, 2006, Nov-15, Volume: 108, Issue:10

    Topics: Acute Disease; Adolescent; Animals; Benzamides; Cell Line; Cell Proliferation; Child; Child, Preschool; DNA, Neoplasm; Drug Synergism; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myeloid; Male; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Cross-Talk; Sirolimus; STAT Transcription Factors; Tandem Repeat Sequences; Transfection

2006
Philadelphia chromosome unmasked as a secondary genetic change in acute myeloid leukemia on imatinib treatment.
    Leukemia, 2006, Volume: 20, Issue:11

    Topics: Acute Disease; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines

2006
Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells.
    Oncogene, 2007, May-24, Volume: 26, Issue:24

    Topics: Animals; Benzamides; Bone Marrow Cells; Carcinogenicity Tests; CCAAT-Enhancer-Binding Protein-alpha; Cell Proliferation; Chemokines, CC; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Homeodomain Proteins; Imatinib Mesylate; Leukemia, Myeloid; Macrophage Inflammatory Proteins; Mice; Mice, Inbred C3H; Mice, SCID; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Repressor Proteins; Tumor Cells, Cultured

2007
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:1

    Topics: Apoptosis; bcl-X Protein; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Microtubules; Monocytes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxazepines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Pyrroles

2007
Gleevec may be heart toxic.
    DukeMedicine healthnews, 2007, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Pyrimidines

2007
A case report of therapeutic leukapheresis in an adult with chronic myelogenous leukemia presenting with hyperleukocytosis and leukostasis.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2007, Volume: 11, Issue:2

    Topics: Adult; Antineoplastic Agents; Benzamides; Blood Viscosity; Chronic Disease; Humans; Imatinib Mesylate; Leukapheresis; Leukemia, Myeloid; Leukocytosis; Leukostasis; Male; Piperazines; Pyrimidines; Retinal Hemorrhage

2007
Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment.
    Medical mycology, 2008, Volume: 46, Issue:3

    Topics: Aged; Benzamides; Candida; Candidiasis; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lung; Male; Opportunistic Infections; Piperazines; Pneumonia; Polymorphism, Genetic; Pyrimidines; Radiography; Toll-Like Receptor 2; Toll-Like Receptor 4

2008
Induction of apoptosis increases expression of non-canonical WNT genes in myeloid leukemia cell lines.
    Oncology reports, 2007, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Benzamides; Caspase 3; Cell Line, Tumor; Cyclin D1; Etoposide; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Wnt Proteins

2007
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
    Blood cells, molecules & diseases, 1997, Volume: 23, Issue:3

    Topics: Apoptosis; Benzamides; Cell Differentiation; Cell Division; Cell Line; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured

1997
Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
    Oncogene, 1999, Feb-11, Volume: 18, Issue:6

    Topics: Apoptosis; Aspartic Acid; Benzamides; Calcium-Calmodulin-Dependent Protein Kinases; Caspase Inhibitors; Caspases; Enzyme Activation; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; U937 Cells

1999
In search of the silver bullet.
    Fortune, 2001, May-14, Volume: 143, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Computers; Creativity; Entrepreneurship; Environmental Pollution; Humans; Imatinib Mesylate; Internet; Leukemia, Myeloid; Piperazines; Pyrimidines; Research; Technology; United States; Vaccines

2001
Anti-cancer drug success emerges from molecular biology origins.
    Trends in pharmacological sciences, 2001, Volume: 22, Issue:7

    Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myeloid; Molecular Biology; Piperazines; Protein-Tyrosine Kinases; Pyrimidines

2001
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
    Blood, 2002, May-01, Volume: 99, Issue:9

    Topics: Acute Disease; Adult; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 9; DNA-Binding Proteins; ETS Translocation Variant 6 Protein; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-ets; Pyrimidines; Recurrence; Repressor Proteins; Translocation, Genetic

2002
chemdatabank.com